{
    "id": 13144,
    "fullName": "ABL2 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ABL2 amp indicates an increased number of copies of the ABL2 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 27,
        "geneSymbol": "ABL2",
        "terms": [
            "ABL2",
            "ABLL",
            "ARG"
        ]
    },
    "variant": "amp",
    "createDate": "10/21/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8797,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) did not inhibit viability of ABL2 amplified lung adenocarcinoma cell lines in culture (PMID: 26758680).",
            "molecularProfile": {
                "id": 13315,
                "profileName": "ABL2 amp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8798,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) did not inhibit viability of ABL2 amplified lung small cell carcinoma cells in culture (PMID: 26758680).",
            "molecularProfile": {
                "id": 13315,
                "profileName": "ABL2 amp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13315,
            "profileName": "ABL2 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 6974,
                    "name": "ABL Inhibitor (pan)",
                    "profileName": "ABL2 amp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}